READ WATCH AND DO
READ
Ageless, by Andrew Steele e Delve into the cutting-edge research that shows how scientists may one day be able to stop us from ageing, and the steps that we can take right now to help slow down the process. £20, Bloomsbury
WATCH
Davina McCall: Sex, Myths and the Menopause The presenter reveals her own struggles with a raft of symptoms caused by hormonal changes, while busting myths around the menopause and using hormone replacement therapy. 9pm, Wednesday, Channel 4
DO
Wandering Wild This three-day expedition for naturelovers around Dartmoor National Park is a walking challenge that’s good for the body and soul. Expect wild swimming and glorious sunsets. From £280, including food and tent. wanderingwild.co.uk
WHILE big pharma stocks are defensive stocks, biotech is anything but. The vaccine race has highlighted the difference between these two parts of the healthcare industry, but also their need to work together.
Gareth Blades, at investment firm Amati, says: ‘The past year has seen big pharma businesses work with smaller nimble biotech companies or research institutions to generate highly innovative products – drugs and treatments that the pharma companies can then plug into their manufacturing and commercial infrastructure.’
Some of these biotech minnows fail catastrophically. Others, such as Novavax, have seen their share prices rocket thanks to vaccine breakthroughs. Investors can get exposure to a diversified portfolio of these exciting biotech minnows through several funds. RTW Venture and Syncona focus on cuttingedge science while BB Biotech, Biotech Growth and International Biotechnology specialise in the biotech sector.